Results 181 to 190 of about 1,411,950 (341)

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Topoisomerases as Targets for Novel Drug Discovery. [PDF]

Pharmaceuticals (Basel)
Perdih A.
europepmc   +1 more source

Where traditional drug discovery meets modern technology in the quest for new drugs [PDF]

, 2017
Mohammed M. Al Qaraghuli, Abdullah R. Alzahrani, Kanidta Niwasabutra, Mohammad A. Obeid, Valerie A. Ferro   +4 more
openalex  

The Construction of the Chiral Quaternary Carbon in the Drug Discovery Directed towards the Novel Neuroprotective Agent E2050

, 2003
Noboru Yamamoto, Yoshihiko Norimine, Teiji Kimura   +2 more
openalex   +2 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Target and biomarker exploration portal for drug discovery. [PDF]

Bioinformatics
Dewangan B, Ray D, Ren Y, Srivastava S, Jiang L, Ojha M, Xu D, Srivastava G.   +7 more
europepmc   +1 more source

Enzyme inhibition in drug discovery and development. The good and the bad.

, 2010
Maria Paola Costi
openalex   +1 more source

Correction: Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens

, 2020
J. E. Camp, Simbarashe B. Nyamini, Fraser J. Scott   +2 more
openalex   +2 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Drug Discovery Strategies for Kallikrein-Related Peptidases. [PDF]

Int J Mol Sci
Dreyer T, Schuster D, Magdolen V, Goettig P.   +3 more
europepmc   +1 more source